← All Bioxcel Therapeutics, INC filings

Bioxcel Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
BTAI
Bioxcel Therapeutics, INC
10-K: BioXcel Therapeutics Faces Going Concern Doubt Amidst Mounting Losses and Clinical Setbacks
BioXcel Therapeutics reported significant operating losses and declining product revenue for 2025, raising substantial doubt about its ability to continue as a going concern, despite positive clinical trial data for IGALMI's at-home use and ongoing capital raises.
NASDAQ
BTAI
Bioxcel Therapeutics, INC
10-K: BioXcel Therapeutics Navigates Financial Challenges While Advancing Neuroscience Pipeline
BioXcel Therapeutics faces financial headwinds but remains focused on clinical development of BXCL501 and exploring strategic options.
NASDAQ
BTAI
Bioxcel Therapeutics, INC
10-K: BioXcel Therapeutics Outlines Share Structure and Regulatory Framework in 10-K Filing
BioXcel Therapeutics' 10-K filing details the company's share structure, governance, and regulatory landscape, highlighting its focus on AI-driven drug development in neuroscience and immuno-oncology.